Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 45 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2012 |
| End Date: | October 2013 |
| Contact: | Deborah Strootman, BSN |
| Email: | dstrootman@shc.arizona.edu |
| Phone: | 520-626-1201 |
Clopidogrel Resistance and Platelet Reactivity in Hispanic Females Undergoing Percutaneous Coronary Intervention
Plavix (clopidogrel) is a drug that is approved by the FDA (Food and Drug Administration) to
reduce the risk of having another heart attack by preventing platelets (blood cells that are
important in forming blood clots) from sticking together and forming another clot. Platelet
activity can be measured by a machine called VerifyNow.
The purpose of this study is to see whether Hispanic women and White non-Hispanic women have
the same platelet response to a commonly used drug, Plavix (clopidogrel). Recent studies
have shown that platelets may be more active in Hispanics, making it more difficult to
prevent clots from forming, even when using Plavix. In addition, studies have shown that
women may also have more active platelets than men. There have been no studies of Hispanic
women and the effect of Plavix on platelet activity.
reduce the risk of having another heart attack by preventing platelets (blood cells that are
important in forming blood clots) from sticking together and forming another clot. Platelet
activity can be measured by a machine called VerifyNow.
The purpose of this study is to see whether Hispanic women and White non-Hispanic women have
the same platelet response to a commonly used drug, Plavix (clopidogrel). Recent studies
have shown that platelets may be more active in Hispanics, making it more difficult to
prevent clots from forming, even when using Plavix. In addition, studies have shown that
women may also have more active platelets than men. There have been no studies of Hispanic
women and the effect of Plavix on platelet activity.
Inclusion Criteria:
- All females age 45 or greater, presenting to University of Arizona Medical Center
South Campus or University Campus Cardiology service with a history of ACS
- Hispanics will be defined via self-reporting as having both parents of Latino descent
- Currently taking clopidogrel
Exclusion Criteria:
- Taking any of the following antiplatelet drugs:
- Prasugrel (Effient)
- Ticagrelor (Brilinta)
- Ticlopidine (Ticlid)
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials